FDA Approves Second Biosimilar – Inflectra™ – The First Monoclonal Antibody Biosimilar
The U.S. Food and Drug Administration announced on April 5 its second ever approval of a biosimilar – Inflectra (infliximab-dyyb) – for multiple indications. Inflectra was developed by Celltrion Inc. and licensed to Pfizer Inc., for treatment of rheumatoid arthritis, inflammatory bowel diseases and other conditions. Inflectra is a biosimilar to Remicade which has been […]
|
3 min read
DW
Daniel S. Wittenberg
Partner